Paysign(US:PAYS)2021-11-10 01:14Financial Data and Key Metrics Changes - The company reported net revenue of $7.8 million for Q3 2021, an increase of $7.9 million year-over-year and a sequential increase of $1.1 million or 16.8% [7] - Adjusted EBITDA for the quarter was $955,000, representing a nearly threefold increase compared to Q2 2021 [7] - Gross margin for the quarter was 51.1%, supported by the conclusion of two pharmaceutical programs [19] - The net loss for the quarter was $271,000, with total operating expenses at $4.2 million [20] Business Line Data and Key Metrics Changes - Plasma revenue accounted for $7 million, up $1.8 million from the same period last year, with an average revenue per month per plasma center of $6,542 [18][22] - Pharma revenue for Q3 2021 was $660,000, an increase of $6 million compared to Q3 2020, driven by changes in accounting estimates [18][23] - The patient affordability vertical saw the launch of three new programs during the quarter, with additional programs expected to launch in Q4 [10][12] Market Data and Key Metrics Changes - Total gross funds loaded increased by 24.7% year-over-year and 7.6% sequentially [8] - Plasma gross funds loaded increased by 42.7% year-over-year and 10.3% from the previous quarter [8] - The company ended the quarter with 359 plasma centers, having onboarded seven additional centers [9][22] Company Strategy and Development Direction - The company aims to bridge gaps left by competitors by leveraging its unique capabilities at the intersection of FinTech and healthcare [15] - Continued investments in patient affordability products and personnel are planned to support growth [12][25] - The company expects to onboard a total of 10 additional plasma centers by the end of the year [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth in both plasma and patient affordability segments, despite ongoing challenges from the pandemic [14] - The company anticipates total revenue for the full year to be in the range of $29 million to $32 million, reflecting growth of 20% to 32% [27] - Adjusted EBITDA guidance for the full year has been increased to a range of $1.3 million to $1.9 million [27] Other Important Information - The company exited the quarter with $6.9 million in unrestricted cash and zero debt, indicating a solid financial position [26] - Depreciation and amortization expenses are expected to be approximately $2.5 million for the full year [29] Q&A Session Summary - No specific questions or answers were recorded in the provided content, as the call concluded without a Q&A segment [31][32]